Zobrazeno 1 - 10
of 68
pro vyhledávání: '"Marjorie C. Green"'
Autor:
Lajos Pusztai, Gabriel N. Hortobagyi, Bryan T. Hennessy, Massimo Cristofanilli, Chafika Mazouni, Fabrice Andre, Attila Tordai, W. Fraser Symmans, Cornelia Liedtke, Marjorie C. Green, Ana M. Gonzalez-Angulo, Kenneth R. Hess, Jaime A. Mejia
Publikováno v:
Journal of Clinical Oncology. 41:1809-1815
PURPOSE Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) expression. In this study, we compared response to neoadjuvant chemotherap
Autor:
Syed A. Hussain, Nicholas J. Vogelzang, Margitta Retz, Xiaodong Shen, Yohann Loriot, Ugo De Giorgi, Alain Ravaud, Marjorie C. Green, Thomas Powles, Sanjeev Mariathasan, Na Cui, Gwenaelle Gravis, Aristotelis Bamias, Priti S. Hegde, Daniel Castellano, Romain Banchereau, Stéphane Oudard, Edward E. Kadel, Ignacio Duran, Aude Flechon, Christina Louise Derleth, Toshimi Takano, Ning Leng, Michiel S. van der Heijden
Publikováno v:
The Lancet. 391:748-757
Summary Background Few options exist for patients with locally advanced or metastatic urothelial carcinoma after progression with platinum-based chemotherapy. We aimed to assess the safety and efficacy of atezolizumab (anti-programmed death-ligand 1
Autor:
K. L. Blackwell, Véronique Diéras, José Baselga, Silke Hoersch, Ian E. Krop, Luca Gianni, Manfred Welslau, Sunil Verma, David Miles, Marjorie C. Green, Jin Xu, Mark D. Pegram
Publikováno v:
The Lancet Oncology. 18:732-742
Summary Background The antibody–drug conjugate trastuzumab emtansine is indicated for the treatment of patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane. Approval of this drug was based on progres
Autor:
Li-Fen Liu, David F. McDermott, Jinzhen Fan, Susheela Carroll, Michael B. Atkins, Alexander R. Abbas, Ning Leng, Robert J. Motzer, Habib Hamidi, Darren Tayama, Thomas Powles, Sanjeev Mariathasan, Christina Schiff, Bernard Escudier, Hartmut Koeppen, Romain Banchereau, Mahrukh Huseni, Jennifer C Lin, Brian I. Rini, Priti Hegde, Kenji Hashimoto, Marjorie C. Green
Publikováno v:
Cancer Cell
Summary Integrated multi-omics evaluation of 823 tumors from advanced renal cell carcinoma (RCC) patients identifies molecular subsets associated with differential clinical outcomes to angiogenesis blockade alone or with a checkpoint inhibitor. Unsup
Autor:
S. Verma, B Kang, David Miles, J Xu, Ian E. Krop, Mark D. Pegram, Manfred Welslau, Marjorie C. Green, L. Gianni, J. Baselga, K. L. Blackwell, Véronique Diéras
Publikováno v:
Cancer Research. 76:P4-14
Introduction T-DM1 is indicated for the treatment of advanced HER2-positive MBC in patients who previously received trastuzumab and a taxane (separately or in combination) based on data from the phase 3 EMILIA study (BO21977/TDM4370g; NCT00829166). I
Autor:
Boris Alekseev, Toni K. Choueiri, Brian I. Rini, Camillo Porta, Ugo De Giorgi, Begoña Mellado, Motohide Uemura, Walter M. Stadler, Howard Gurney, Bohuslav Melichar, Alain Ravaud, David F. McDermott, Mahrukh Huseni, Robert E. Hawkins, Cristina Suarez, Elisabeth Piault-Louis, Frede Donskov, Michael B. Atkins, S. Li, Gretchen Frantz, Marjorie C. Green, Robert J. Motzer, Tarik Khaznadar, Christina Schiff, Thomas Powles, Bernard Escudier, Alpa Thobhani, Michael Staehler, Sergio Bracarda, Francis Parnis, Jae-Lyun Lee, Jens Bedke
Publikováno v:
Rini, B I, Powles, T, Atkins, M B, Escudier, B, McDermott, D F, Suarez, C, Bracarda, S, Stadler, W M, Donskov, F, Lee, J L, Hawkins, R, Ravaud, A, Alekseev, B, Staehler, M, Uemura, M, De Giorgi, U, Mellado, B, Porta, C, Melichar, B, Gurney, H, Bedke, J, Choueiri, T K, Parnis, F, Khaznadar, T, Thobhani, A, Li, S, Piault-Louis, E, Frantz, G, Huseni, M, Schiff, C, Green, M C & Motzer, R J 2019, ' Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151) : a multicentre, open-label, phase 3, randomised controlled trial ', The Lancet, vol. 393, no. 10189, pp. 2404-2415 . https://doi.org/10.1016/S0140-6736(19)30723-8
Summary Background A phase 2 trial showed improved progression-free survival for atezolizumab plus bevacizumab versus sunitinib in patients with metastatic renal cell carcinoma who express programmed death-ligand 1 (PD-L1). Here, we report results of
Autor:
Loan Somarriba, Edward E. Kadel, Marjorie C. Green, Alessandra Castiglioni, Mattias Höglund, Yohann Loriot, Lawrence Fong, Jennifer M. Giltnane, Thomas Powles, Shannon J. Turley, Daniel L. Halligan, Yinghui Guan, Richard Bourgon, Priti S. Hegde, Gregg Fine, Johannes Riegler, Hartmut Koeppen, Yasin Senbabaoglu, Michiel S. van der Heijden, Dorothee Nickles, Yulei Wang, Kathryn Mesh, Steve Lianoglou, Daniel Sheinson, James Ziai, Jillian L. Astarita, Christina Louise Derleth, Jeffrey Hung, Yagai Yang, Richard A.D. Carano, Suchit Jhunjhunwala, Andrew A. Pierce, Stephen Santoro, Rafael Cubas, Cecile Chalouni, Jonathan E. Rosenberg, Daniel S. Chen, Pontus Eriksson, Ira Mellman, Sanjeev Mariathasan, Kobe C. Yuen, Romain Banchereau
Publikováno v:
Nature, vol 554, iss 7693
Nature
Nature
Therapeutic antibodies that block the programmed death-1 (PD-1)-programmed death-ligand 1 (PD-L1) pathway can induce robust and durable responses in patients with various cancers, including metastatic urothelial cancer. However, these responses only
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e591c377ddf7bd53a278239d3ca959c4
https://escholarship.org/uc/item/46h483w1
https://escholarship.org/uc/item/46h483w1
Autor:
Susan Dent, Anthony Gonçalves, Joo-Hee Yi, Alexander Strasak, Pat LoRusso, Sandhya Girish, Priya Agarwal, Chunze Li, Marjorie C. Green
Publikováno v:
Cancer Research. 75:P4-15
Introduction Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate comprising trastuzumab, a stable linker, and the microtubule inhibitor DM1. In phase 3 studies of HER2-positive metastatic breast cancer (MBC), T-DM1 significantly increased p
Autor:
Li Tao, Juan Yang, Lisa Wang, Christina A. Clarke, Laura Chu, Marjorie C. Green, Scarlett Lin Gomez, Lisa M. Moy, Chunyan Song
Publikováno v:
Cancer Research. 75:P3-07
Background: Guidelines describe recommended BC treatments (tx) according to tumor subtype; however, population-based data regarding tx utilization are limited. Objective: To describe tx utilization by tumor HER2, hormone receptor (HR) status, and sta
Autor:
Laura Chu, Li Tao, Lisa M. Moy, Lisa Wang, Marjorie C. Green, Melissa Brammer, Christina A. Clarke, Scarlett Lin Gomez, Chunyan Song
Publikováno v:
Cancer Research. 75:P3-07
BACKGROUND: Breast cancer (BC) that is metastatic at initial diagnosis (i.e. de novo metastatic or stage IV) has not been well described, especially in the general population. OBJECTIVE: To describe demographics, tumor characteristics and survival in